Compare Alcon AG (ALC) vs iShares MSCI China ETF (MCHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alcon AG vs iShares MSCI China ETF — how do they compare? Alcon AG trades at $74.19 (market cap $36.44B), while iShares MSCI China ETF trades at $55.86. The key difference: Alcon AG pays a 0.48% dividend while iShares MSCI China ETF pays none, and Alcon AG is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals.
| ALC | MCHI | |
|---|---|---|
Market Cap | $36.44B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $90.12 | $66.99 |
52-Week Low | $62.02 | $50.48 |
Enterprise Value | $40.28B | — |
Dividend Yield | 0.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MCHI trades at $56.57, up 1.19% with strong technical momentum showing bullish moving averages and institutional buying interest. The ETF benefits from China's export strength and AI-driven manufacturing growth, though key financial ratios remain undisclosed. Recent news highlights China's 23% July export surge and $295 billion AI infrastructure plan, creating positive sentiment around Chinese equities.
Outlook remains cautiously optimistic with technical indicators signaling strength but RSI levels suggesting potential overbought conditions. Key risks include US-China trade tensions and regulatory uncertainties, while institutional flows and China's tech investment push provide upside catalysts for continued momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →
